Related Experiment Video
Updated: Jul 17, 2025
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
The Potential of Trastuzumab Deruxtecan as a Tissue Agnostic Drug
1Medical Science, Dx-Rx Institute, Fredensborg, Denmark.
Background:
Many modern anticancer drugs are designed to target specific molecular alterations harbored by the cancer. If a specific drug is able to target these alterations, regardless of the organ or tissue in which the cancer originates, it will often be characterized as a tissue- or tumor agnostic drug. According to the Food and Drug Administration (FDA), a tissue-agnostic drug refers to a drug that targets a specific molecular alteration across multiple cancer types, as defined by organ, tissue, or tumor type.
Summary:
Over the last 6 years, the FDA has approved seven tissue-agnostic drugs, and more are anticipated in the future. One promising candidate for a tissue-agnostic classification is the antibody-drug conjugate trastuzumab deruxtecan (T-DXd). Currently, T-DXd is approved for the treatment of human epidermal growth factor receptor 2 (HER2)-positive and HER2-low breast cancer, HER2-positive gastric or gastroesophageal junction adenocarcinoma, and non-small cell lung cancer with activating HER2 mutations. Ongoing clinical research is exploring the potential of T-DXd in various solid tumors that harbor specific HER2 molecular alterations, and encouraging results, including the interim data from the DESTINY-PanTumor02 trial, have been published, which suggest a tissue-agnostic potential.
Key Messages:
Published phase I data as well as the interim results from the phase II DESTINY-PanTumor02 trial indicates that patients with different HER2-positive advanced solid tumors may benefit from treatment with T-DXd. Based on the currently available data, it seems likely that T-DXd possesses pantumor activity. However, different clinical trials are ongoing, and it will be necessary to see the results from these trials before drawing a final conclusion. When discussing tissue-agnostic potential, it is important to add that for most of the patients enrolled in the DESTINY-PanTumor02 and other trials, few treatment alternatives seem to exist, and T-DXd might be able to cover an unmet medical need.
Insights
Trastuzumab deruxtecan shows promise as a tissue-agnostic drug, potentially treating various HER2-positive advanced solid tumors. Further research is ongoing to confirm its broad efficacy and address unmet medical needs.
Area of Science:
- Oncology
- Molecular Biology
- Drug Development
Background:
- Modern anticancer drugs increasingly target specific molecular alterations.
- Tissue-agnostic drugs target these alterations regardless of cancer origin.
- The FDA defines tissue-agnostic drugs by their molecular target across cancer types.
Purpose of the Study:
- To evaluate the tissue-agnostic potential of trastuzumab deruxtecan (T-DXd).
- To assess T-DXd's efficacy in HER2-positive advanced solid tumors.
- To identify potential new treatment options for patients with limited alternatives.
Main Methods:
- Review of published Phase I data.
- Analysis of interim results from the Phase II DESTINY-PanTumor02 trial.
- Exploration of ongoing clinical research in various solid tumors with HER2 alterations.
Main Results:
- Trastuzumab deruxtecan (T-DXd) is approved for specific HER2-positive and HER2-low cancers.
- Interim data suggest T-DXd may benefit patients with diverse HER2-positive advanced solid tumors.
- Preliminary findings indicate potential pantumor activity for T-DXd.
Conclusions:
- T-DXd demonstrates promising pantumor activity in HER2-positive advanced solid tumors.
- Ongoing trials are crucial to confirm T-DXd's tissue-agnostic classification.
- T-DXd may address significant unmet medical needs in patients with few treatment options.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38Mitogens and the Cell Cycle